New Treatment for Canine Leishmaniosis
Author Information
Author(s): Miró Guadalupe, Segarra Sergi, Cerón José Joaquín, Ferrer Lluís, Solano-Gallego Laia, Montell Laia, Costa Ester, Teichenne Joan, Mariné-Casadó Roger, Roura Xavier
Primary Institution: Universidad Complutense de Madrid
Hypothesis
Does adding dietary nucleotides and AHCC to the standard treatment improve outcomes in dogs with leishmaniosis?
Conclusion
The new treatment protocol shows additional benefits, including reduced parasite load and improved kidney function in dogs with leishmaniosis.
Supporting Evidence
- Adding the supplement resulted in further significant improvements in reducing the parasite load.
- Improvements in kidney function were observed in the supplement group.
- Daily intake of the supplement was safe and well tolerated over two years.
- Both groups showed significant improvements in clinical scores over time.
- Relapse rates were lower in the supplement group compared to the control group.
Takeaway
This study found that a new supplement can help sick dogs with leishmaniosis feel better and stay healthier.
Methodology
A multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted with 160 dogs, where 97 were randomized to receive either a supplement or placebo alongside standard treatment.
Potential Biases
Potential bias due to the study design and the exclusion of certain demographics.
Limitations
Missing data for the period between days 30 and 180 and potential impact of concomitant diseases were not evaluated.
Participant Demographics
Dogs of any age, breed, or gender with naturally occurring leishmaniosis were included.
Statistical Information
P-Value
p=0.004
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website